Shares of Danish drugmaker Novo Nordisk climbed more than 5% on Friday after early U.S. prescription data suggested an encouraging start for Wegovy’s new oral formulation. The pill began commercial availability on Jan. 5 following U.S. approval in late December, and preliminary datasets for the week ending Jan. 9 show thousands of prescriptions filled. Analysts called the opening “solid” while cautioning that one data point is not definitive for long-term demand. The results revive hopes that Novo Nordisk can regain ground against rival Eli Lilly in the fast-growing obesity and diabetes medicines market.
Key Takeaways
- Wegovy oral launched commercially on Jan. 5, 2026 after late-December approval; early trading saw Novo Nordisk shares rise over 5% on Jan. 16, 2026.
- IQVIA data cited by Leerink Partners show about 3,100 Wegovy pill prescriptions filled in the drug’s first week (week ending Jan. 9, 2026).
- Symphony data (reported via Bloomberg) indicate roughly 4,290 Wegovy pill prescriptions in its first full week, with most fills for the starting dose.
- For comparison, Eli Lilly’s injectable Zepbound recorded ~1,300 prescriptions in its first week and about 8,000 in the second week after its launch; Symphony reported ~1,900 Zepbound fills in its first full week.
- Analysts warn available datasets may omit direct-to-consumer pharmacy and telehealth channel fills, which could materially change the totals.
- Wegovy is a peptide GLP-1 therapy that requires no food or drink for 30 minutes after dosing; Eli Lilly’s upcoming oral orforglipron is a small-molecule pill without that restriction.
Background
GLP-1–based therapies have reshaped the obesity and diabetes treatment landscape in recent years, driving strong patient and prescriber interest and high revenue growth for major manufacturers. Novo Nordisk and Eli Lilly emerged as the market leaders after several clinical successes and regulatory approvals; injectable formulations like Wegovy (injectable) and Zepbound previously dominated early commercial activity. The oral Wegovy launch represents Novo Nordisk’s strategic move to offer a pill option, potentially lowering barriers for patients who prefer oral dosing.
Market share shifted in early 2025 when Eli Lilly captured a majority of prescriptions in key channels, in part driven by aggressive commercial rollout and popular assets. Manufacturers are now racing to capture both the prescription volume and prescribing momentum as new oral formulations enter the market. Payers, telehealth companies and direct-to-consumer pharmacies have become important distribution routes that can rapidly scale access but are not always captured in third-party syndicated datasets.
Main Event
The U.S. commercial launch of Wegovy’s oral formulation took place on Jan. 5, 2026, after the product received approval in late December 2025. Two independent data sources produced near-term snapshots: IQVIA (cited by Leerink Partners) and Symphony (reported through Bloomberg). IQVIA-based figures showed approximately 3,100 prescriptions filled in Wegovy’s opening week; Symphony reported roughly 4,290 fills in the first full week, with most patients starting on the initial dose.
TD Cowen analysts described the opening as a “solid start” but emphasized that a single weekly snapshot cannot establish a persistent demand trajectory. They and other analysts noted that some channels—specifically, Novo Nordisk’s direct-to-consumer pharmacy and affiliated telehealth partners—may not be reflected in the syndicated datasets, which would undercount total early volume. That caveat leaves room for upward revision when fuller channel data are tallied.
Market reaction also reflects competitive context: Eli Lilly’s injectable Zepbound had a stronger multi-week ramp in its launch period (about 1,300 prescriptions first week and ~8,000 second week), and Lilly is expected to introduce its own oral agent, orforglipron, to the market in the coming months. Analysts say that while Novo Nordisk’s pill has first-mover status for a GLP-1 oral indicated for weight loss, differences in formulation and dosing instructions could influence uptake.
Analysis & Implications
Short-term prescription counts matter because they signal prescriber willingness to try new products and indicate how quickly distribution partners can scale. The early numbers suggest meaningful initial demand for an oral GLP-1 option, which could expand the patient pool beyond those willing to take injections. If direct-to-consumer channels are sizeable and are later added to totals, the launch may be substantially stronger than syndicated data now show.
However, clinical and practical differences between products are important. Novo Nordisk’s oral Wegovy is a peptide-based formulation that requires patients to wait 30 minutes after dosing before eating or drinking—an instruction that can complicate daily routines and reduce convenience. Eli Lilly’s oral candidate is a small-molecule drug without that post-dose restriction, which may be an advantage for adherence and prescriber preference if efficacy and safety profiles are comparable.
From an investor perspective, the 5% share uptick reflects renewed confidence that Novo Nordisk can defend or expand market presence despite Eli Lilly’s earlier gains. But sustainable market share will depend on three factors: (1) how many total prescriptions are captured across all channels, (2) real-world adherence and persistence with the oral regimen, and (3) the competitive response when Lilly’s oral product launches. Payer coverage policies and prior authorization burdens will also shape adoption.
Comparison & Data
| Product / Source | First-week fills (approx.) |
|---|---|
| Wegovy (oral) — IQVIA (week ending Jan. 9, 2026) | 3,100 |
| Wegovy (oral) — Symphony (first full week) | 4,290 |
| Zepbound (injectable) — initial commercial week | ~1,300 |
| Zepbound (injectable) — second week | ~8,000 |
| Zepbound — Symphony (first full week) | ~1,900 |
The table summarizes different syndication sources and counts reported for the earliest commercial weeks. Differences between IQVIA and Symphony totals likely reflect varying panel coverage, reporting delays and whether certain retail or specialty channels are included. Analysts caution that a fully accurate market picture will need integrated channel reporting that includes direct-to-consumer and telehealth fills.
Reactions & Quotes
“This looks like a solid start for the first-ever weight-loss pill, though one data point does not make a trend.”
TD Cowen analyst (via research note)
TD Cowen framed the early numbers as encouraging but urged caution pending broader datasets that include all distribution channels.
“IQVIA shows roughly 3,100 fills in week one, a reasonable opening compared with prior launches.”
David Risinger, Leerink Partners (summarizing IQVIA)
Leerink Partners pointed to IQVIA figures to place Wegovy’s opening in the context of earlier product rollouts and to highlight the need for multi-week comparisons.
Unconfirmed
- The precise volume of Wegovy prescriptions routed through Novo Nordisk’s direct-to-consumer pharmacy and telehealth partners is not included in syndicated IQVIA or Symphony snapshots and has not been publicly disclosed.
- Discrepancies between IQVIA and Symphony figures imply differing coverage; which dataset most accurately reflects total U.S. fills is currently unresolved.
- The timing and market impact of Eli Lilly’s oral orforglipron (expected in coming months) remain subject to regulatory, manufacturing and commercial scheduling that could shift.
Bottom Line
Early prescription data indicate that Wegovy’s oral launch has attracted meaningful initial demand and prompted a positive market reaction for Novo Nordisk, but analysts uniformly caution that these are first-week snapshots. Full assessment of commercial performance requires integrated data across retail, specialty, direct-to-consumer and telehealth channels, as well as multi-week persistence and adherence metrics.
Competition from Eli Lilly—especially if orforglipron reaches market without dosing restrictions—will be a key determinant of how market shares evolve. For investors, prescribers and payers, the next two to three quarters of data will be essential to understand whether the oral GLP-1 segment expands total patient reach or primarily redistributes prescriptions among incumbent therapies.
Sources
- CNBC (news report summarizing IQVIA/Symphony and analyst notes) — media
- IQVIA (healthcare analytics firm) — data provider
- Novo Nordisk (company) — official
- Eli Lilly and Company (company) — official
- Bloomberg (news outlet reporting Symphony data) — media